Cardiff Oncology (CRDF) Fundamental Analysis: Revenue, Earnings & Valuation

5.45 / 10

Netural

Fundamental health scores 5.5/10, deemed fair. Revenue‑to‑market and cash‑to‑market ratios are strong, supporting valuation. However, fixed‑asset turnover and income‑tax‑to‑profit ratios raise concerns. Overall, fundamentals are moderate with limited upside.

Analysis Checks(7/10)

Revenue-MV

Value-4.96

Score2/3

Weight22.05%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value-13.18

Score2/3

Weight-2.17%

1M Return-1.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight17.97%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight4.10%

1M Return1.69%

PB-ROE

Value1.95

Score3/3

Weight28.19%

1M Return9.74%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-1.04%

1M Return-0.50%

Fixed assets turnover ratio

Value0.80

Score1/3

Weight-2.51%

1M Return-1.24%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight10.39%

1M Return4.32%

Asset-MV

Value-0.55

Score0/3

Weight7.06%

1M Return2.69%

Cash-MV

Value0.02

Score2/3

Weight15.96%

1M Return5.94%

Is CRDF undervalued or overvalued?

CRDF scores 5.45/10 on fundamentals and holds a Fair valuation at present. Backed by its -71.49% ROE, -7732.04% net margin, -2.35 P/E ratio, 2.38 P/B ratio, and 27.37% earnings growth, these metrics solidify its Netural investment rating.